U.S. markets close in 3 hours 13 minutes

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7750+0.0065 (+0.85%)
As of 03:59PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.7685
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range0.7500 - 0.7899
52 Week Range0.5800 - 21.7000
Avg. Volume2,150,232
Market Cap7.253M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-10.1400
Earnings DateNov 13, 2023 - Nov 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ADMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adamis Pharmaceuticals Corporat
    Analyst Report: Cisco Systems, Inc.Cisco Systems is the largest provider of networking equipment in the world and one of the largest software companies in the world. Its largest businesses are selling networking hardware and software (where it has leading market shares) and cybersecurity software like firewalls. It also has collaboration products, like its Webex suite, and observability tools. It primarily outsources its manufacturing to third parties and has a large sales and marketing staff—25,000 strong across 90 countries. Overall, Cisco employees 80,000 employees and sells its products globally.
    Fair Value
    Economic Moat
    7 months agoMorningstar
View more
  • GlobeNewswire

    Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus

    Company to begin trading under new ticker symbol “DMK” on September 8, 2023SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders. In conjunction with the name change, the company’s common stock is expected

  • GlobeNewswire

    Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

    SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 Corporate Highlights In May, the Company closed the merger with DMK Pharmaceuticals Corporation (DMK), a private, clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on de

  • GlobeNewswire

    Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering

    SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and